Amanta Healthcar

Why is Amanta Healthcare Ltd falling/rising?

As of 01-Sep, Amanta Healthcare Ltd's stock price is at 190.90, reflecting a 1.98% increase. The stock has shown strong growth with a 75.62% year-to-date rise, although a decrease in investor participation may raise concerns for future trading activity.

As of 01-Sep, Amanta Healthcare Ltd's stock price is rising, currently at 190.90, reflecting an increase of 3.7 or 1.98%. This upward movement is supported by the stock's performance over the last two days, during which it has gained 4%. Additionally, it has outperformed its sector by 2.58% today. <BR><BR>In the context of longer-term performance, the stock has shown a significant increase of 13.63% over the past month and an impressive 75.62% year-to-date, indicating strong overall growth despite a slight decline of 2.03% over the past week. The stock is currently trading above its 20-day, 50-day, 100-day, and 200-day moving averages, which typically suggests a positive trend.<BR><BR>However, it is important to note that there has been a decrease in investor participation, with delivery volume falling by 56.61% against the 5-day average, which could indicate a potential concern for future trading activity. Despite this, the stock remains liquid enough for trading, allowing for continued interest from investors. Overall, the combination of recent gains, strong year-to-date performance, and current trading conditions contribute to the rise in Amanta Healthcare Ltd's stock price.

What does Amanta Healthcar do?

Amanta Healthcare Ltd, a Micro Cap company in the Pharmaceuticals & Biotechnology sector, reported net sales of 69 Cr and a net profit of 3 Cr for June 2026. Originally incorporated in 1994, it has undergone several name changes, with its current name adopted in 2014.

Overview:<BR>Amanta Healthcare Ltd operates in the Pharmaceuticals & Biotechnology industry and is classified as a Micro Cap company.<BR><BR>History:<BR>The company was originally incorporated in 1994 as Marck Parenterals (India) Limited. It underwent several name changes, becoming Marck Biosciences Limited in 2005 and finally Amanta Healthcare Limited in 2014. The most recent quarterly results reported net sales and net profit for June 2026.<BR><BR>Financial Snapshot:<BR>Net Sales: 69 Cr (Quarterly Results - Jun 2026) <BR>Net Profit: 3 Cr (Quarterly Results - Jun 2026) <BR>Market Cap: INR 713 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 45.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.69 <BR>Return on Equity: 7.30% <BR>Price to Book: 3.24 <BR><BR>Contact Details:<BR>Registrar Address: Not available. <BR>Phone: N/A <BR>Email: N/A <BR>Website: N/A

Who are the peers of the Amanta Healthcar?

Amanta Healthcar's peers include Kopran, Bharat Parenter., Wanbury, Anlon Healthcare, Anuh Pharma, Shree Ganesh Rem, Bafna Pharma, Zim Laboratories, and Kilitch Drugs. Management risk varies from excellent at Anlon Healthcare and Kilitch Drugs to below average at Bharat Parenter. and Bafna Pharma, with Bafna Pharma showing the highest 1-year return at 198.53%.

Peers: The peers of Amanta Healthcar are Kopran, Bharat Parenter., Wanbury, Anlon Healthcare, Anuh Pharma, Shree Ganesh Rem, Bafna Pharma., Zim Laboratories, and Kilitch Drugs.<BR><BR>Quality Snapshot: Excellent management risk is observed at Anlon Healthcare and Kilitch Drugs, while Average management risk is found at Kopran, Wanbury, Zim Laboratories, and the rest. Below Average management risk is present at Bharat Parenter., Bafna Pharma., and Anuh Pharma. Growth is Excellent at Anlon Healthcare, Average at Kopran, Wanbury, Zim Laboratories, and Kilitch Drugs, and Below Average at Bharat Parenter., Shree Ganesh Rem, Bafna Pharma., Amanta Healthcar, Anuh Pharma, and the rest. Capital Structure is Excellent at Anuh Pharma and Shree Ganesh Rem, Good at Kopran and Kilitch Drugs, and Below Average at Bharat Parenter., Wanbury, Bafna Pharma., Amanta Healthcar, Zim Laboratories, and the rest.<BR><BR>Return Snapshot: Bafna Pharma. has the highest 1-year return at 198.53%, while Wanbury has the lowest at -8.90%. Amanta Healthcar's 1-year return is not available for comparison. Additionally, peers with negative six-month returns include Wanbury and Bafna Pharma.

How big is Amanta Healthcar?

As of 31st August, Amanta Healthcare Ltd has a market capitalization of 713.00 Cr, with recent net sales of 291.17 Cr and a net profit of 14.68 Cr. Shareholder's funds are 220.21 Cr and total assets amount to 557.98 Cr as of March 2026.

As of 31st August, Amanta Healthcare Ltd has a market capitalization of 713.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Amanta Healthcare reported Net Sales of 291.17 Cr and a Net Profit of 14.68 Cr.<BR><BR>The latest reporting period for the balance sheet is March 2026, with Shareholder's Funds amounting to 220.21 Cr and Total Assets of 557.98 Cr.

Which are the latest news on Amanta Healthcar?

Should I buy, sell or hold Amanta Healthcare Ltd?

When is the next results date for Amanta Healthcare Ltd?

The next results date for Amanta Healthcare Ltd is August 5, 2026.

The next results date for Amanta Healthcare Ltd is scheduled for August 5, 2026.

Are Amanta Healthcare Ltd latest results good or bad?

Amanta Healthcare Ltd's latest results show a mixed performance, with a net profit increase of 19.44% and revenue growth of 6.84%, but a decline in operating margins and ongoing operational challenges suggest the results are not entirely favorable. The company needs to address these issues for sustainable growth and profitability.

Amanta Healthcare Ltd's latest results present a mixed picture. On the positive side, the company reported a net profit of ₹5.53 crores for Q4 FY26, which is a significant increase of 19.44% compared to the previous quarter. Additionally, revenue grew by 6.84% year-on-year, reaching ₹76.99 crores, marking the highest quarterly revenue in recent times.<BR><BR>However, there are notable concerns as well. The operating margin has declined to 19.42%, down from 20.62% in the previous quarter and significantly lower than 26.31% in the same quarter last year. This decline indicates potential challenges in pricing power or increased costs, which could affect profitability moving forward.<BR><BR>Moreover, while the company has shown some improvement in net profit, it remains below the previous year's figures, reflecting ongoing operational challenges. The average return on equity (ROE) of 8.18% and return on capital employed (ROCE) of 13.97% over the past five years suggest that the company is facing issues with capital efficiency and profitability.<BR><BR>In summary, while there are positive aspects such as revenue growth and improved net profit, the decline in margins and underlying operational challenges indicate that the results are not entirely favorable. The company is at a critical juncture, needing to address these issues to ensure sustainable growth and profitability.